The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2022
Filed:
Jul. 03, 2018
Applicant:
Torque Therapeutics, Inc., Cambridge, MA (US);
Inventors:
Thomas L. Andresen, Vanlose, DK;
De-Kuan Chang, Cambridge, MA (US);
Douglas S. Jones, Bellevue, WA (US);
Jesse Lyons, Cambridge, MA (US);
Jonathan D. Nardozzi, Watertown, MA (US);
Ulrik B. Nielsen, Quincy, MA (US);
Michael Feldhaus, Grantham, NH (US);
Assignee:
Torque Therapeutics, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 38/20 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C12N 5/16 (2006.01); C12N 15/88 (2006.01); A61P 37/06 (2006.01); A61K 39/395 (2006.01); C07K 14/765 (2006.01); C12N 5/0783 (2010.01); A61K 9/00 (2006.01); A61K 47/65 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 38/2086 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 14/765 (2013.01); C07K 16/289 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2845 (2013.01); C07K 16/2866 (2013.01); C12N 5/0637 (2013.01); C12N 5/163 (2013.01); C12N 15/88 (2013.01); A61K 9/0019 (2013.01); A61K 47/65 (2017.08); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01); C12N 2501/2315 (2013.01);
Abstract
Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.